expect report adj ep miss consensu due fewer
offset reimburs pressur similar see lead downward
revis guidanc focu quarter potenti lever mitig
headwind also highlight l-t strategi choic toward partnership vs vert integr
recent affirm po comment
estim report adj ep consensu
believ reflect management recent comment realiz less contribut
offset reimburs pressur retail usa expect enter year
moder brand inflat estim net revenu
consensu also estim adj oper incom
consensu
similar issu face retail pharmaci busi note recent
confer see higher reimburs pressur lever off-set
reimburs pressur less management expect enter year expect
similar impact retail usa busi impact retail/
busi differ time given differ two
compani fiscal year end assum greater gross margin degrad retail
usa partial off-set moder brand inflat result retail
usa adj oper incom estim repres y/i
growth previou base increment impact retail
usa adj oper profit guidanc retail/ltc segment assum
percentag point declin adj oper incom guidanc due
continu reimburs pressur without full benefit tradit offset includ
declin benefit gener
expect downward revis guidanc adj ep primarili
due lower expect offset reimburs pressur retail usa
also think could downsid guidanc slower pace brand
inflat although management state impact huge magnitud one
quarter recent confer management note saw brand inflat compar
closer year ago estim coupl percentag point weaker
expect brand inflat equal gross profit adj ep factor
revis assumpt believ could revis lower adj ep guidanc
repres y/i growth due headwind relat off-set
reimburs pressur estim impact adj ep lower brand
inflat anoth potenti posit offset includ faster pace cost reduct
surfac one might view issu earli indict /aet
merger move integr model care case given fact
yet even embark path futur vision integr care
pleas see page report import disclosur
market perform rate think compani weakli posit
transit toward value-bas care rel peer other pharma
suppli chain manag care industri consolid integr medic
pharmaci data stand still reliant tradit retail pharmaci
model believ leav expos potenti disrupt also
think ownership acquisit aet rather partnership open health
hub necessari realiz benefit cost trend improv without
see potenti margin distribut channel greater risk
disrupt furthermor manag consist meet exceed adj ep
estim fare well base oper metric think indic
challeng macro environ
y/i top-lin growth driven
growth part acquisit
alliancerx includ fep contract
margin pressur continu
share repo
y/i top-lin growth high-singl
lower expect margin pressur
share repo greater
benefit disrupt cvs/aet
greater expect margin pressur
walgreen oper largest drugstor chain compani sell product
servic retail drugstor mail telephon on-line
channel within store walgreen sell prescript non-prescript drug
well gener merchandis includ household item conveni fresh food
person care beauti care photofinish candi primarili within retail locat
walgreen oper take clinic walgreen also oper specialti infus
respiratori servic mail servic
deliveri model issu similarli issu retail pharmaci
continu margin pressur seemingli structur near-term fewer lever
off-set pressur bigger question chang model
allevi pressur altogeth embark vertically-integr
approach instead chosen store-in-stor partnership strategi mani
partnership still pilot phase previous cautiou strategi
fit value-bas environ interestingli recent analyst day
compani spoke posit partnership note valu
patient come primari care clinic also abl attend need
includ fill prescript narrowli thought logic
want one coordin care path take approach
appear one provid infrastructur other coordin care
time benefit greater traffic announc partnership remain
mostli pilot phase anecdot evid suggest approach may
find success margin posit long-term strategi
lower adj ep est
respect also lower pt base revis dcf analysi
impli share trade adj ep estim
current multipl
million expect per share data
thomson eikon cowen compani
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end august cowen
million except per-shar data
compani report cowen compani
fifo cost fifo gross fifo gross chang lifo lifo gross lifo gross equiti earn ab- adjust equiti earn adjust oper adjust oper expens pre-tax pre-tax tax incom tax tax earn equiti method net earn non-controlling adjust net total net averag dilut adjust chang gross gross oper year end august cowen
million except per-shar data
compani report cowen compani
fifo cost fifo gross fifo gross chang lifo lifo gross lifo gross equiti earn ab- adjust equiti earn adjust oper adjust oper expens pre-tax pre-tax tax incom tax tax earn equiti method net earn non-controlling adjust net total net averag dilut adjust chang gross gross oper cowen
million
compani report cowen compani
asset cash account receiv current current properti intang non-curr total current liabil short-term trade account accru expens incom current long-term defer incom non-curr stockhold equiti common paid-in employe stock loan retain accumul comprehens treasuri non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end august cowen
million
compani report cowen compani
income/ loss flow oper activ depreci gain previous held equiti interest- share base compens unreal gain fair valu adjustments- defer incom invest impair chang oper asset liabil receiv current non-curr account accru expens incom non-curr net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end august cowen
million
compani report cowen compani
flow oper activ net adjust reconcil net earn net cash depreci loss allianc boot call sale business- defer incom stock compens incom tax save employe stock plans- chang oper asset liabil account receiv current trade account accru expens incom non-curr asset net cash provid oper flow invest activitiesaddit properti proce sale leaseback transactions- purchas short-term invest held proce short-term invest held purchas short-term invest avail sale- proce sale short-term invest avail sale- return invest restrict cash- proce sale busi intang asset acquisit net cash payment proce sale invest invest allianc boots- net cash use invest flow financ activitiesnet payment short-term borrowings- payment long-term proce financ issuanc long-term debt- stock proce relat employe stock dividend net cash provid use financ effect exchang rate chang cash cash equivalents- chang equivalentsnet decreas cash cash cash equival begin cash equival end year end august cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
number company-specif risk associ pt includ loss
share disrupt entiti wors expect reimburs pressur better
expect gener procur wbad meaning acquisit
